Klotho Neurosciences

Klotho Neurosciences (formerly Anew Medical, Inc., officially renamed in September 2024) focuses on areas of high unmet medical needs, committed to unlocking the potential of biologic therapies, cell therapies, and gene therapies. The company expands the application of protein, cell, and gene therapies to highly prevalent neurodegenerative diseases such as Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and Parkinson’s disease, as well as cancer and other age-related conditions. Collaborating with top research institutions, Klotho Neurosciences has built a robust pipeline of gene therapy candidates. The company’s vision is to leverage its proprietary patented gene therapy research projects while discovering, developing, and commercializing novel gene therapies and in vitro diagnostic products for neurodegenerative diseases and other age-related conditions, establishing itself as a leader in the field of gene therapy for neurodegenerative diseases.